FARMINGDALE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced plans to release second quarter fiscal year 2009 financial results on Monday afternoon, February 9, 2009. Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Monday, February 9, 2009 to discuss the Company's second quarter fiscal 2009 financial results.
Shareholders and other interested parties may participate in the conference call by dialing (800) 659-2056 (domestic) or (617) 614-2714 (international) and entering access code 58959521, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.
A recording of the live-call will be available approximately 2 hours after the event through February 16, 2009. The dial-in number to listen to the recording is (888) 286 8010 or (617) 801 6888. The replay access code is 94431439.
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Misonix Contact: Investor Relations Contact: Richard Zaremba Kevin M. McGrath Chief Financial Officer Cameron Associates, Inc. 631-694-9555 212-245-4577 firstname.lastname@example.org Kevin@cameronassoc.com
|SOURCE Misonix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved